Skip to main content

Table 3 The reason of discontinuation

From: A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01)

Course No.

No. of discontinued patients

Reason of discontinuation

Adverse event

Recurrence

Other

1

9

Gastrointestinal, 6

Myelosuppression, 1 Cholangitis, 1

Chest pain, 1

–

–

2

4

Gastrointestinal, 2 Myelosuppression, 1

1

–

3

1

–

1

–

4

2

–

2

–

5

1

–

1

–

6

1

–

–

Traffic accident, 1

7

1

–

–

House-moving, 1

8

2

Stomatitis 1

1

–